Hc Biopharma Inc.
Clinical trials sponsored by Hc Biopharma Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to control advanced lung cancer Results expected Dec 2026 (estimated)
- New hope for lung cancer: experimental drug HC010 enters phase 2 trial Results expected Dec 2026 (estimated)
- New lupus drug candidate enters early human safety testing Results expected Mar 2027 (estimated)
- Can a copy of a cancer antibody match the original in the body? Results expected Jun 2027 (estimated)
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called HC010 combined with chemotherapy in people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. About 331 participants will join, and researchers will also…
Phase 1 • Sponsor: HC Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo aims to control advanced lung cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called HC010 combined with chemotherapy in people with advanced lung cancer that has spread or come back. The main goal is to find a safe dose and check for side effects. About 328 adults will take part, and researchers will also see if the…
Phase 1 • Sponsor: HC Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for lung cancer: experimental drug HC010 enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug called HC010 in people with advanced non-small cell lung cancer that has a specific marker (PD-L1). The goal is to see if the drug can shrink tumors and control the disease. About 50 participants will receive the treatment, and researchers will monitor…
Phase 2 • Sponsor: HC Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can a copy of a cancer antibody match the original in the body?
Knowledge-focused Recruiting nowResearchers are testing whether a cetuximab injection made by HC Biopharma behaves the same way in the body as Erbitux, an approved cetuximab product. The study enrolls about 92 healthy men aged 18 to 46 who receive one intravenous infusion of either the test product or Erbitux. …
Phase 1 • Sponsor: HC Biopharma Inc. • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC